comparemela.com
Home
Live Updates
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS : comparemela.com
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...
Related Keywords
California ,
United States ,
Jeffrey Cohen ,
Paul Tyahla ,
Eric Goldstein ,
Ralph Kern ,
Chaim Lebovits ,
California Institute For Regenerative Medicine ,
Brainstorm Cell Therapeutics Inc ,
Lifesci Advisors ,
Drug Administration ,
Cleveland Clinic Mellen Center ,
Free Communications ,
Nasdaq ,
Brainstorm Cell Therapeutics Ltd ,
National Ms Society ,
European Medicines Agency ,
Research In Multiple Sclerosis ,
European Committee For Treatment ,
Brainstorm Cell Therapeutics ,
Efficacy Study ,
Progressive Multiple ,
European Committee ,
Multiple Sclerosis ,
Experimental Therapeutics ,
Chief Executive Officer ,
Chief Medical Officer ,
Storm Cell Therapeutics ,
Orphan Drug ,
California Institute ,
Regenerative Medicine ,
Harbor Statement ,
Sci Advisors ,
Cell Therapeutics ,
comparemela.com © 2020. All Rights Reserved.